Latest News

© Crystal light - © Crystal light - stock.adobe.com.
AstraZeneca and Daiichi Sankyo Share Positive Data From Phase III DESTINY-Breast09 Trial of Enhertu Plus Pertuzumab

June 2nd 2025

In the DESTINY-Breast09 study, Enhertu (fam-trastuzumab deruxtecan-nxki) plus pertuzumab reduced the risk of disease progression or death by 44% in patients with HER2-positive metastatic breast cancer.

How FDA Cuts Are Creating New Bottlenecks in Clinical Operations
How FDA Cuts Are Creating New Bottlenecks in Clinical Operations

June 2nd 2025

Credit: peopleimages.com | stock.adobe.com.
America’s Vanishing Scientific Research Workforce is a Threat to Public Health

June 2nd 2025

The Hidden Impact of Drug Pricing on Government Clinical Trials
The Hidden Impact of Drug Pricing on Government Clinical Trials

May 30th 2025

© Dr_Microbe - © Dr_Microbe - stock.adobe.com
Investigational MK-1084 Demonstrates Antitumor Activity in Phase I Trial for Colorectal and Non-Small Cell Lung Cancers

May 30th 2025

Applied Clinical Trials April 2025

Check out the latest features and columns!

Check out the latest features and columns!

Conference Coverage

View All
© Egor - © Egor - stock.adobe.com
Notable Discussions from SCOPE 2025: Aiming to Calculate, Accommodate, and Innovate for Enhanced Drug Development

March 11th 2025

Set the Course for a More Engaging & Productive Patient & Clinical Trial Site Journey
Set the Course for a More Engaging & Productive Patient & Clinical Trial Site Journey

February 26th 2025

SCOPE Summit 2025: Shakthi Kumar Talks Real-World Data Use in Clinical Development
SCOPE Summit 2025: Shakthi Kumar Talks Real-World Data Use in Clinical Development

February 24th 2025

SCOPE Summit 2025: Graham Clark on Ensuring Data Consitency Amid the Rise of Real-World Evidence
SCOPE Summit 2025: Graham Clark on Ensuring Data Consitency Amid the Rise of Real-World Evidence

February 21st 2025

Latest Videos
Podcasts

All News

© 2025 MJH Life Sciences

All rights reserved.